多药耐药(Multidrug reststence,MDR)是白血病化疗失败的主要原因,它与细胞内的MDR基因及细胞膜表面P-170糖蛋白的过度表达密切相关。我们应用抗P-170的JSB-1单抗对75例髓细胞白血病患者的P-170糖蛋白进行检测,分析它与临床治疗效果的关系,探讨P-170过度表达与髓细胞白血病预后之间的关系。现报告如下。 1 材料和方法 1.1 病例:75例髓细胞白血病血样标本取自西安医科大学一附院血液科、省医院血液科门诊和住院病人。全部病例均经骨髓细胞学、免疫分型确诊,并按FAB标准分型。75例患者中男34例,女41例;年龄18～70岁。其中AML45例,分为初治 Multidrug resistance (MDR) is the main cause of leukemia chemotherapy failure. It is closely related to the overexpression of MDR gene and P-170 glycoprotein on the cell surface. We used anti-P-170 JSB-1 monoclonal antibody to detect P-170 glycoprotein in 75 patients with myeloid leukemia, analyze its relationship with the clinical treatment effect, and explore the relationship between P-170 overexpression and the prognosis of myeloid leukemia. Relationship. The report is as follows. 1 Materials and methods 1.1 Cases: 75 cases of myeloid leukemia blood samples were taken from the Department of Hematology of the First Affiliated Hospital of Xi’an Medical University, Department of Hematology of the Provincial Hospital and inpatients. All cases were confirmed by bone marrow cytology and immunophenotyping, and were classified according to the FAB standard. Among the 75 patients, 34 were males and 41 were females; they were 18 to 70 years old. Among them, 45 cases of AML were divided into primary treatment